-
Mashup Score: 2How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 1 year(s) ago
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 08-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam - 1 year(s) ago
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
8-month PSA outcomes of men with #mCSPC in the #PEACE1 phase 3 trial. Gwenaëlle Gravis Mescam, MD @univamu joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/bFSrgjPKwk https://t.co/KTK06a6huP
-
-
Mashup Score: 0How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 2 year(s) ago
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4aYqO @ASCO https://t.co/tIfsAYrUPZ
-
-
Mashup Score: 0
Alicia Morgans is joined by Bertrand Tombal who provides a European perspective highlighting prostate cancer data we have seen so far this year starting with the ARASENS and PEACE-1 data. Dr. Tombal’s discussion highlights key points for the community to focus on including the messages around maximal androgen blockade and PARP inhibitors. Biographies: Bertrand Tombal, MD, PhD, Chairman of the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Treatment considerations in advanced #ProstateCancer. @BertrandTOMBAL @UCLouvain_be joins @CaPsurvivorship @DanaFarber to discuss #ARASENS and #PEACE1 data as well as the messages around maximal androgen blockade and PARP inhibitors. #WatchNow > https://t.co/3FJOM51t03 https://t.co/x5OV4BD8Mn
-
-
Mashup Score: 0How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 2 year(s) ago
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4bwgm @ASCO https://t.co/Q93UD12hpN
-
-
Mashup Score: 3ESMO 2022: 8-Month PSA Strongly Predicts Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - 2 year(s) ago
ESMO 2022 8-month PSA decline to undetectable levels, EACE-1 phase 3 trial, ADT plus docetaxel or abiraterone acetate plus prednisone, men with de novo mCSPC in the PEACE-1 phase 3 trial, ADT+/- docetaxel +/- abiraterone acetate + prednisone.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive #ProstateCancer in the #PEACE1 phase 3 trial. Presentation by Gwenaelle Gravis @paoli_calmettes. #ESMO21 written coverage by @zklaassen_md @GACancerCenter > https://t.co/qhwp32nWiu @myESMO https://t.co/moL7a01EhK
-
-
Mashup Score: 0
Alicia Morgans is joined by Bertrand Tombal who provides a European perspective highlighting prostate cancer data we have seen so far this year starting with the ARASENS and PEACE-1 data. Dr. Tombal’s discussion highlights key points for the community to focus on including the messages around maximal androgen blockade and PARP inhibitors. Biographies: Bertrand Tombal, MD, PhD, Chairman of the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Treatment considerations in advanced #ProstateCancer. @BertrandTOMBAL @UCLouvain_be joins @CaPsurvivorship @DanaFarber to discuss #ARASENS and #PEACE1 data as well as the messages around maximal androgen blockade and PARP inhibitors. #WatchNow > https://t.co/3FJOM4JS8v https://t.co/PVmxkGbeNY
-
-
Mashup Score: 1How Do the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi - 2 year(s) ago
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4aYqO @ASCO https://t.co/eu4ZniFYgG
-
-
Mashup Score: 2
Alicia Morgans is joined by Bertrand Tombal who provides a European perspective highlighting prostate cancer data we have seen so far this year starting with the ARASENS and PEACE-1 data. Dr. Tombal’s discussion highlights key points for the community to focus on including the messages around maximal androgen blockade and PARP inhibitors. Biographies: Bertrand Tombal, MD, PhD, Chairman of the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Treatment considerations in advanced #ProstateCancer. @BertrandTOMBAL @UCLouvain_be joins @CaPsurvivorship @DanaFarber to discuss #ARASENS and #PEACE1 data as well as the messages around maximal androgen blockade and PARP inhibitors. #WatchNow > https://t.co/3FJOM4JS8v https://t.co/7ZMOAI1akT
-
-
Mashup Score: 0
Alicia Morgans is joined by Bertrand Tombal who provides a European perspective highlighting prostate cancer data we have seen so far this year starting with the ARASENS and PEACE-1 data. Dr. Tombal’s discussion highlights key points for the community to focus on including the messages around maximal androgen blockade and PARP inhibitors. Biographies: Bertrand Tombal, MD, PhD, Chairman of the…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Treatment considerations in advanced #ProstateCancer. @BertrandTOMBAL @UCLouvain_be joins @CaPsurvivorship @DanaFarber to discuss #ARASENS and #PEACE1 data as well as the messages around maximal androgen blockade and PARP inhibitors. #WatchNow > https://t.co/3FJOM4JS8v https://t.co/5nypHkwhZb
-
How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4aYqO @ASCO https://t.co/d5sRH8p3ue